Mirae Asset Global Investments Co. Ltd. boosted its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 208,494 shares of the medical research company’s stock after purchasing an additional 3,182 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Edwards Lifesciences were worth $17,235,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Alliancebernstein L.P. lifted its position in shares of Edwards Lifesciences by 27.5% during the 4th quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock valued at $1,632,040,000 after acquiring an additional 4,712,819 shares during the period. Moneta Group Investment Advisors LLC lifted its position in shares of Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock valued at $1,148,938,000 after acquiring an additional 15,384,593 shares during the period. Brown Advisory Inc. lifted its position in shares of Edwards Lifesciences by 0.8% during the 4th quarter. Brown Advisory Inc. now owns 14,341,102 shares of the medical research company’s stock valued at $1,069,990,000 after acquiring an additional 115,268 shares during the period. Geode Capital Management LLC lifted its position in shares of Edwards Lifesciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 12,136,243 shares of the medical research company’s stock valued at $903,771,000 after acquiring an additional 205,714 shares during the period. Finally, Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $658,390,000. 79.78% of the stock is currently owned by institutional investors and hedge funds.
Edwards Lifesciences Trading Down 0.6 %
EW stock opened at $79.55 on Friday. The company has a market cap of $48.36 billion, a price-to-earnings ratio of 35.20, a PEG ratio of 4.34 and a beta of 1.02. The company has a quick ratio of 2.30, a current ratio of 3.15 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $88.51 and a 200-day simple moving average of $84.26. Edwards Lifesciences Co. has a 52 week low of $67.13 and a 52 week high of $107.18.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on EW. Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences from $75.00 to $87.00 in a research note on Monday, April 24th. Wells Fargo & Company raised their price objective on shares of Edwards Lifesciences from $78.00 to $90.00 in a research note on Thursday, April 27th. TheStreet raised shares of Edwards Lifesciences from a “c+” rating to a “b-” rating in a research note on Wednesday, April 19th. Truist Financial raised their price objective on shares of Edwards Lifesciences from $101.00 to $105.00 in a research note on Wednesday, July 19th. Finally, Jefferies Financial Group raised their price objective on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the stock a “buy” rating in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $92.68.
Insider Buying and Selling
In related news, VP Catherine M. Szyman sold 5,000 shares of the company’s stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $85.81, for a total transaction of $429,050.00. Following the completion of the sale, the vice president now directly owns 35,056 shares of the company’s stock, valued at approximately $3,008,155.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 6,640 shares of the company’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $88.68, for a total value of $588,835.20. Following the completion of the transaction, the vice president now directly owns 172,090 shares of the company’s stock, valued at approximately $15,260,941.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Catherine M. Szyman sold 5,000 shares of the company’s stock in a transaction dated Tuesday, June 13th. The shares were sold at an average price of $85.81, for a total transaction of $429,050.00. Following the completion of the transaction, the vice president now directly owns 35,056 shares of the company’s stock, valued at $3,008,155.36. The disclosure for this sale can be found here. In the last three months, insiders sold 217,666 shares of company stock valued at $19,258,019. Company insiders own 1.29% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Insider Buying Explained: What Investors Need to Know
- 3 Best Meme ETFs to Buy Now
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- XPO Keeps Reaching New Highs: Markets Love the Stock
- Comparing and Trading High PE Ratio Stocks
- Starbucks Market at a Turning Point: Is a Breakout Imminent?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
